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The ferredoxin reductase FdR9 from Thermobifida fusca, a member of the
oxygenase-coupled NADH-dependent ferredoxin reductase (FNR) family,
catalyses electron transfer from NADH to its physiological electron acceptor
ferredoxin. It forms part of a putative three-component cytochrome P450
monooxygenase system in T. fusca comprising CYP222A1 and the [3Fe–4S]-
cluster ferredoxin Fdx8 as well as FdR9. Here, FdR9 was overexpressed and
purified and its crystal structure was determined at 1.9 Å resolution. The overall
structure of FdR9 is similar to those of other members of the FNR family and
is composed of an FAD-binding domain, an NAD-binding domain and a
C-terminal domain. Activity measurements with FdR9 confirmed a strong
preference for NADH as the cofactor. Comparison of the FAD- and NAD-
binding domains of FdR9 with those of other ferredoxin reductases revealed the
presence of conserved sequence motifs in the FAD-binding domain as well as
several highly conserved residues involved in FAD and NAD cofactor binding.
Moreover, the NAD-binding site of FdR9 contains a modified Rossmann-fold
motif, GxSxxS, instead of the classical GxGxxG motif.
1. Introduction
Ferredoxin reductases (FdRs) are essential components of the
electron-transfer chains of three-component cytochrome P450
monooxygenases (Hannemann et al., 2007). FdR9 from the
actinobacterium Thermobifida fusca belongs to the oxygenase-
coupled NADH-dependent ferredoxin reductase family
of FAD-dependent electron-transfer enzymes [ferredoxin-
NAD(P)H reductases; EC 1.18.1.3] (Vorphal et al., 2017). It
mediates the transfer of two electrons from NADH to an iron–
sulfur cluster-containing ferredoxin via two successive one-
electron transfer steps (Medina & Gómez-Moreno, 2004).
Electron transfer between the ferredoxin reductase and the
ferredoxin requires the formation of a ternary NADH–FdR–
Fdx complex (Deng et al., 1999; Kuznetsov et al., 2005).
T. fusca is a moderately thermophilic soil bacterium
(Bachmann & McCarthy, 1991) and is a rich source of thermo-
stable enzymes for application in biocatalysis (Wilson, 2004).
In the genome of T. fusca (Lykidis et al., 2007), the gene coding
for FdR9 (Tfu_1273) lies adjacent to the genes encoding
CYP222A1 (Tfu_1274) and a putative [3Fe–4S]-cluster ferre-
doxin named Fdx8 (Tfu_1275). Based on this genomic place-
ment, FdR9, Fdx8 and CYP222A1 are believed to form a
three-component cytochrome P450 monooxygenase system.
Here, we report the heterologous production, purification,
crystallization and structure determination of FdR9, one of
ISSN 2053-230X
the physiological protein partners of this three-component
system. The aim of this study was to provide a structural basis
for further investigations of the intermolecular electron-
transfer processes between FdR9 and Fdx8 as well as the
associated protein–protein interactions.
2. Materials and methods
2.1. Macromolecule production
The gene encoding FdR9 (Tfu_1273) was provided by
Professor Vlada Urlacher (Institute of Biochemistry II,
Heinrich-Heine University, Düsseldorf, Germany) in the
plasmid pET-22b(+). The gene was subcloned from pET-
22b(+) into the vector pET-28a(+) using the restriction
enzymes NdeI and EcoRI to include an N-terminal His6 tag
fused to the resulting protein and a thrombin recognition site
between the His tag and the FdR9 sequence. FdR9 was
overexpressed in Escherichia coli C43(DE3) cells (Miroux &
Walker, 1996; Dumon-Seignovert et al., 2004) transformed
with the Tfu_1273-containing pET-28a(+) vector. For func-
tional expression, the bacteria were grown in 1 l TB medium
supplemented with 50 mg l1 kanamycin at 37C. At an OD600
of 0.8, expression was induced by the addition of isopropyl
-d-1-thiogalactopyranoside to a final concentration of
0.5 mM. After expression for 16 h at 240 rev min1 and 37C,
the culture was harvested by centrifugation (15 min at 4400g
and 4C). The cell pellet was resuspended in 24 ml lysis buffer
(20 mM Tris pH 8.0, 300 mM NaCl) in the presence of
protease inhibitors (one tablet of Complete EDTA-free per
50 ml; Sigma–Aldrich). After sonication (nine cycles of 20 s at
an amplitude of 60% followed by a 10 s pause on ice using
a Vibra-Cell VCX130, Sonics & Materials, USA) for cell
disruption and subsequent centrifugation (15 min, 10 000g,
4C) to remove cell debris, FdR9 was found in the soluble
fraction. The His6-tag-containing FdR9 was purified by affinity
chromatography on an ÄKTAprime FPLC system (GE
Healthcare, Freiburg, Germany) using a 5 ml HisTrap column
(GE Healthcare). The bound protein was eluted using a linear
imidazole gradient (0–0.5 M) in five column volumes (CV).
Selected FdR9-containing fractions were combined for incu-
bation with the Thrombin CleanCleave Kit (Sigma–Aldrich)
and were then dialyzed against 20 mM Tris pH 8.0, 40 mM
NaCl at 4C for 16 h. Dialyzed samples were again loaded
onto a HisTrap column (GE Healthcare) to remove the
cleaved His tag. The FdR9-containing flowthrough was loaded
onto a 5 ml HiTrap Q HP column (GE Healthcare) and
elution was performed using a linear NaCl gradient (0.04–
1 M) in 5 CV. Selected FdR9-containing fractions were
concentrated by ultrafiltration using a 30 kDa cutoff membrane
(Amicon Ultra-15, Merck) and were further purified by gel
filtration on a Superdex 75 26/60 column (GE Healthcare)
using 20 mM Tris pH 8.0, 300 mM NaCl, 1 mM dithiothreitol.
Purified FdR9 was obtained with a yield of 60 mg per litre of
culture and displayed a yellow color indicative of the flavin
cofactor. A high degree of purity was confirmed for FdR9 by
the observation of a single band on a 12% SDS–PAGE gel.
Macromolecule-production information is summarized in
Table 1.
2.2. Crystallization
Initial crystallization trials were carried out at room
temperature in 96-well Intelli-Plates (Art Robbins Instru-
ments, Sunnyvale, California, USA) with the Index screen
(D’Arcy et al., 2003) using the sitting-drop vapor-diffusion
method. The droplet was initially formed of 200 nl of a solu-
tion consisting of 42 mg ml1 FdR9 in 20 mM Tris pH 8.0,
300 mM NaCl, was mixed with 200 nl reservoir solution using
a pipetting robot (Honeybee 963, Genomic Solutions,
Huntingdon, UK) and was then equilibrated against 60 ml
reservoir solution. Crystals of FdR9 were obtained in condi-
tion C6 of the Index screen, consisting of 1.5 M ammonium
sulfate, 0.1 M NaCl, 0.1 M bis-Tris pH 6.5. The crystals were
yellow-colored as is typical for native FNR crystals owing to
the presence of the flavin cofactor (Morales et al., 2000; Fig. 1).
Trials to optimize the crystal quality by varying the precipitant
concentration or the pH did not result in better diffracting
crystals. Crystallization information is summarized in Table 2.
2.3. Data collection and processing
FdR9 crystals were harvested using a nylon loop (Hampton
Research) and were soaked in reservoir solution containing
20%(v/v) 2,3-(R,R)-butanediol prior to flash-cooling in liquid
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Table 1
Macromolecule-production information.
Source organism T. fusca strain XY
Expression vector pET-28a(+)
Expression host E. coli strain C43(DE3)
Complete amino-acid sequence

















Crystals of ferredoxin reductase FdR9 from T. fusca, with dimensions of
50  50  50 mm, obtained from Index screen condition C6.
nitrogen. 3600 images were collected by the oscillation method
with a range of 0.1 per image on a Dectris PILATUS 6M-F
detector using single-wavelength synchrotron radiation on
beamline X11 at PETRA III of the Deutsches Elektronen-
Synchrotron (DESY), Hamburg, Germany. Reflection-image
processing was performed using DIALS (Winter et al., 2018)
and AIMLESS (Evans & Murshudov, 2013) from the CCP4
suite (Winn et al., 2011). Data-collection and processing
statistics are summarized in Table 3.
2.4. Structure solution and refinement
The initial phases were obtained by molecular replacement
using MrBUMP (Keegan & Winn, 2008) executing Phaser
(McCoy et al., 2007) and using the atomic coordinates of
putidaredoxin reductase (PDB entry 1q1w; Sevrioukova et al.,
2004) as a search model. Refinement was performed by
alternating rounds of REFMAC5 (Murshudov et al., 2011) and
manual adjustments in Coot (Emsley et al., 2010). The final
refinement steps were performed with phenix.refine (Afonine
et al., 2012), including TLS refinement and the addition of
riding H atoms. The FdR9 diffraction data and coordinates
were deposited in the Protein Data Bank (PDB; Berman et al.,
2002) as PDB entry 6tuk. Representations of the structures
were generated with PyMOL version 2.1.1 (Schrödinger, New
York, USA). Refinement statistics are listed in Table 4.
2.5. Reductase activity assay
The activity of FdR9 with NADH and NADPH as cofactors
was determined spectrophotometrically by measuring the
decrease in the ferricyanide concentration at 420 nm ("420 =
1.02 mM1 cm1; Roome et al., 1983). Each 1 ml reaction
contained 0.5 mM K3Fe(CN)6, an appropriate amount of
FdR9 (3.7 mg for the reaction with NADH and 37 mg for the
reaction with NADPH) and 0.5 mM NADH or NADPH in
50 mM potassium phosphate buffer pH 7.4. Measurements
were performed at ambient temperature using a Cary 60
instrument (Agilent, Heilbronn, Germany).
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Table 3
Data collection and processing.




a, b, c (Å) 142.79, 142.79, 142.79
, ,  () 90, 90, 90
Resolution range (Å) 142.79–1.90 (1.94–1.90)
Total No. of reflections 2946416 (144375)
No. of unique reflections 39768 (2527)





Overall B factor from Wilson plot (Å2) 31.74
Table 4
Structure solution and refinement.
Values in parentheses are for the outer shell.
Resolution range (Å) 47.6–1.90 (1.97–1.90)
Completeness (%) 99.81 (100)
No. of reflections, working set 39634 (3887)
No. of reflections, test set 1951 (208)
Final Rcryst 0.185 (0.243)
Final Rfree 0.200 (0.270)






Bond lengths (Å) 0.010
Angles () 0.87





Most favored (%) 97.19
Allowed (%) 2.81
Rotamer outliers (%) 0.33
Table 2
Crystallization.
Method Sitting-drop vapor diffusion
Plate type 96-well Intelli-Plates
Temperature (K) 298
Protein concentration (mg ml1) 42
Buffer composition of protein solution 20 mM Tris pH 8, 300 mM NaCl
Composition of reservoir solution 0.1 M NaCl, 0.1 M bis-Tris pH 6.5,
1.5 M ammonium sulfate
Volume and ratio of drop 200 nl, 1:1
Volume of reservoir (ml) 60
Figure 2
Overall structure of FdR9. The FAD-binding, NAD-binding and
C-terminal domains are colored cyan, light blue and light pink, respectively.
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Figure 3
Multiple sequence alignment of FdR9 and homologous ferredoxin reductases obtained from a DALI search using the FdR9 structure as a template.
Helices are represented by coils and -sheets are shown as arrows. Columns with residues that are more than 70% similar according to physicochemical
properties (threshold set to 0.7) are framed in blue and amino-acid residues with 100% identity are highlighted by a red background. FdR9 residues
involved in hydrogen-bond interactions with the FAD molecule are framed in green boxes. The three loops of BphA4 interacting with the NAD molecule
are framed in black boxes, and the residues of BphA4 interacting with the NAD molecule by hydrogen bonding and hydrophobic interactions are
highlighted by yellow boxes. The PAM250 matrix was used for sequence alignment. The figure was rendered by ESPript 3.0 (Robert & Gouet, 2014).
3. Results and discussion
3.1. Structural overview of FdR9
FdR9 crystallized in space group P4132, with one monomer
in the asymmetric unit. The initial phases were obtained by
molecular replacement using the structure of putidaredoxin
reductase (PDB entry 1q1w; 26% amino-acid sequence iden-
tity) as a search model. The resulting electron-density map
allowed the identification of the FAD molecule bound to the
reductase. The final model of FdR9, refined to an Rcryst of
18.5% and an Rfree of 20.0%, displays very good geometry,
with no residues located in disallowed regions of the Rama-
chandran plot. The structure of FdR9 contains nine -helices
and 25 -strands, which form three distinct domains (Fig. 2):
an FAD-binding domain (residues 1–106 and 223–308), an
NAD-binding domain (residues 107–222) and a C-terminal
domain (residues 309–393). Structural comparison of FdR9
with other proteins using the DALI server (Holm & Sander,
1995) indicated that it is very similar to ferredoxin reductases
from Rhodopseudomonas palustris (PuR), Novosphingobium
aromaticivorans (ArR), Pseudomonas sp. (BphA4) and
P. putida (PdR) (Table 5), all of which share the three-domain
architecture shown in Fig. 2. The root-mean-square deviations
(r.m.s.d.s) for C atoms of these protein structures from the
structure of FdR9 ranged between 1.9 and 2.2 Å. PuR, ArR
and PdR are part of three-component cytochrome P450
monooxygenase systems, like FdR9, but transfer electrons to
[2Fe–2S]-cluster ferredoxins, whereas the physiological inter-
action partner of FdR9 seems to be a [3Fe–4S]-cluster ferre-
doxin. In contrast, BphA4 forms part of the three-component
biphenyl dioxygenase system present in Pseudomonas sp.
(Table 5).
3.2. FAD-binding domain
The FAD-binding domain of FdR9 adopts a typical /-fold
consisting of two antiparallel -sheets and one parallel -sheet
surrounded by four -helices, as shown in Fig. 2. Sequence-
alignment analysis of the FAD-binding domain reveals the
presence of three highly conserved motifs: PYxRPPLSK,
TSxPx3AxG and RxEx4A (Fig. 3). These motifs contain most
of the amino acids that interact with the FAD cofactor. In
FdR9, the FAD cofactor interacts with the protein through a
network of hydrogen bonds to the FAD-binding domain
involving amino-acid residues Leu11, Ala12, Glu35, Arg42,
Lys47, Ala76, Arg119, Asp260 and Trp278 (Fig. 4), several of
which are conserved among the ferredoxin reductases PuR,
ArR, PdR and BphA4 (Fig. 3). The pyrophosphate moiety of
FAD is stabilized by hydrogen bonds between the main-chain
amide groups of Ala12 and Leu11 and O1P and between the
side-chain NH2 group of Arg119 and O2A, as well as between
the Asp260 side chain and the O2P and O30 atoms of the
riboflavin part. Moreover, Arg42 plays an important role in
stabilizing the FAD cofactor through the formation of elec-
trostatic interactions and hydrogen bonds with the O1A atom
of the pyrophosphate moiety and the O3B atom of the
adenosine ribose (Fig. 4). In PdR, this arginine is replaced by
Leu45, while PuR, ArR and BphA4 also carry an arginine at
the respective position (Figs. 3 and 4). Ala76 of FdR9 is
involved in stabilization of the adenine through hydrogen
bonding of the backbone carbonyl O atom to the N6A atom.
The O" atom of Glu35 forms hydrogen bridges with the O2B
and O3B atoms of the adenosine ribose. This glutamate is also
conserved in PuR, ArR and BphA4, whereas an alanine is
present at the corresponding position in PdR (Figs. 3 and 4).
Trp278 stabilizes the isoalloxazine ring of the FAD cofactor by
hydrogen bonding between its backbone NH and the O2 atom
of the isoalloxazine ring. Lys47 in FdR9 forms a salt bridge
with Glu148 and hydrogen bonds to the carbonyl O atom of
Pro43 as well as to the O4 and N5 atoms of the isoalloxazine
ring.
Despite the fact that the overall fold of the FAD domain in
FdR9 is highly similar to the structures of PuR, ArR, PdR and
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Table 5
DALI search against the PDB using the FdR9 structure.







3fg2 (PuR) Rhodopseudomonas palustris strain CGA009 CYP199A2 27 380 46.8 Xu et al. (2009)




30 383 47.5 Yang et al. (2010)
2gqw (BphA4) Pseudomonas sp. Biphenyl dioxygenase BphA1A2 30 382 47.2 Senda et al. (2007)
1q1w (PdR) Pseudomonas putida P450cam 26 386 46.6 Sevrioukova et al. (2004)
Figure 4
Superposition of the FAD-binding site of FdR9 (PDB entry 6tuk, gray)
with the structures of other ferredoxin reductases [PDB entries 3fg2
(PuR), 3lxd (ArR), 2gqw (BphA4) and 1q1w (PdR)]. Residues forming
hydrogen-bond interactions with the FAD cofactor are shown as sticks.
Hydrogen bonds are indicated by dotted lines.
BphA4, with several conserved amino acids interacting with
the FAD molecule, differences can also be observed. The first
difference involves the presence or absence of secondary
structure in the loop region (residues 51–63 in FdR9) of the
five ferredoxin reductases. The short and longer helices found
in this region in PdR, PuR, ArR and BphA4 correspond to a
purely random loop in FdR9 (Fig. 5). It has previously been
proposed that the absence of helix secondary structure in this
region could influence the binding of FAD (Xu et al., 2009).
Another difference is the insertion of five amino acids (resi-
dues 295–300) in a surface loop in FdR9, while this loop is
shorter in the other four reductases (Fig. 3). The electron
density for residues 298–300 in this extended loop in FdR9 is
not well resolved, indicating high flexibility.
3.3. NAD-binding domain
In our FdR9 crystallization experiments we did not attempt
to co-crystallize FdR9 with the nicotinamide cofactor, and
hence the structure of FdR9 presented here does not contain
NAD. Nevertheless, sequence and structural analyses of the
NAD-binding domain of FdR9 indicate the presence of a
canonical Rossmann fold similar to previously reported
complexes, in which the NAD molecule was shown to interact
with three loops [corresponding to residues 140–146 (first
loop), 164–172 (second loop) and 219–224 (third loop) in
FdR9; Fig. 3] (Senda et al., 2000). In PuR, ArR, PdR and
BphA4, the first loop between 9 and 4 contains the typical
GxGxxG motif indicative of nicotinamide cofactor binding,
which is modified to GASWIS in FdR9, with the last two
glycines in the motif replaced by serines (Fig. 3). This change
in the motif does not affect the folding of the respective loop,
as can be seen in the structural comparison between FdR9 and
BphA4 (Fig. 6). Previous studies proposed that the sequence
motif GxGxxG was indicative of NAD specificity, whereas the
motif GxGxxA is found in NADP-binding enzymes, although
exceptions are known (Carugo & Argos, 1997; Hanukoglu,
2017), as would be the case for FdR9. In our studies, FdR9 was
found to display a clear preference for NADH as the cofactor.
Based on a ferricyanide reduction assay (Roome et al., 1983),
the specific activity of FdR9 with NADH was determined to be
104 U mg1, whereas the specific activity with NADPH was
only 1.2 U mg1. Hence, the nicotinamide cofactor-binding
site of FdR9 was compared in more detail with that of BphA4
(PDB entry 1f3p), which was crystallized with NAD bound in
the active site. The comparison shows that FdR9 shares a
similar fold at the entrance to the NAD-binding channel and
an accessible nicotinamide-binding site above the isoallox-
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Figure 6
Structural comparison of the NAD-binding sites of FdR9 (PDB entry 6tuk) and the reductase BphA4 (PDB entry 1f3p) in complex with NAD+. The
amino-acid residues of BphA4 interacting with NAD+ and the corresponding residues in FdR9 are labeled. The loops containing the GxGxxG motif of
BphA4 and the GxSxxS motif of FdR9 are shown in red.
Figure 5
Superposition of the structural model of FdR9 (PDB entry 6tuk, gray)
with the structures of other ferredoxin reductases [PDB entries 3fg2
(PuR) in yellow, 3lxd (ArR) in magenta, 2gqw (BphA4) in green and
1q1w (PdR) in red] to highlight differences in secondary structure in the
random-loop region (residues 51–63 in FdR9).
azine ring of the flavin cofactor. In BphA4, NAD interacts
with Val155, Ile156 and Glu159 in the first loop (the corre-
sponding residues in FdR9 are Trp144, Ile145 and Glu148) and
with Glu175, Thr176, Ser182 and Arg183 in the second loop
(corresponding to Glu164, Ala165, Ser171 and Ala172 in
FdR9). Glu175 of BphA4 forms hydrogen bonds to the O2B
and O3B atoms of the adenosine ribose as well as to Thr176.
The negative charge of Glu175, which is conserved not only
in FdR9 (Fig. 6) but also in PuR, ArR and PdR, has been
proposed to enhance NAD cofactor specificity by repulsion of
the phosphate of NADP (Hanukoglu, 2017). Ser182 in BphA4,
which corresponds to Ser171 in FdR9, also forms a hydrogen
bond to the adenosine ribose O3B atom. Residues in the third
loop interacting with the NAD molecule (Ile235 and Gly236 in
BphA4), as well as Glu289 and Trp320 of BphA4, are signif-
icantly conserved among the five ferredoxin reductases
compared in Fig. 3. Interestingly, FdR9 has a threonine at
position 220 (third loop), while PuR, ArR, PdR and BphA4
possess a hydrophobic residue (either valine or alanine) in the
corresponding position. Of the 11 amino acids directly inter-
acting with the NAD molecule in BphA4 by hydrogen
bonding, eight are conserved in FdR9 (Fig. 3), whereas the
proteins share an overall amino-acid sequence identity of only
30%. In contrast, other loop residues (especially in the first
and second loop), which do not form direct hydrogen-bond
interactions with the nicotinamide cofactor, display a lower
degree of conservation.
Apart from this, FdR9 exhibits two significantly shorter
surface loops in the NAD-binding domain compared with the
other four ferredoxin reductases. This involves the loops
between 8 and 3 as well as between 12 and 13 (Fig. 3).
The latter in particular is seven, seven and nine amino acids
longer in PuR, ArR and PdR, respectively. In PdR this loop is
involved in crystallographic dimer formation, while PuR and
ArR crystallize as monomers like FdR9 (Sevrioukova et al.,
2004; Xu et al., 2009; Yang et al., 2010). It is unclear, however,
whether these differences in surface-loop lengths also have a
possible physiological impact.
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